252690 Epidemiologic Approach to Evaluate Potential for HPV Type Replacement Post-Vaccination

Monday, October 31, 2011: 4:50 PM

Joseph Tota, BSc, MSc , Divison of Cancer Epidemiology, McGill, Montreal, QC, Canada
Agnihotram V. Ramana-Kumar, PhD , Department of Oncology, McGill, Montreal, QC, Canada
François Coutlée, MD , Département de microbiologie, Université de Montréal, Montreal, QC, Canada
Luisa Villa, PhD , Hospital Alemão Oswaldo Cruz, Ludwig Institute for Cancer Research, São Paulo, Brazil
Harriet Richardson, PhD , Department of Community Health and Epidemiology, Queen's University, Kingston, ON, Canada
Ann Burchell, PhD , Divison of Cancer Epidemiology, McGill, Montreal, QC, Canada
Anita Koushik, PhD , Environmental Epidemiology and Population Health Research Group, Université de Montréal, Montreal, QC, Canada
Marie Hélène Mayrand, MD, PhD , Département d'obstétrique-gynécologie, Université de Montréal, Montreal, QC, Canada
Eduardo Franco, DPH , Divison of Cancer Epidemiology, McGill, Montreal, QC, Canada
Background: Two vaccines prevent the HPV genotypes that cause the majority of cervical cancers. It is possible that the distribution of the other high-risk types will change following the elimination of these vaccine types, a phenomenon referred to as type-replacement (TR). Objectives: Using HPV DNA typing data, we addressed the potential for TR by: comparing the observed (O) versus expected (E) number of coinfections involving vaccine types with other HPV types, and evaluating whether infection with specific HPV types affects acquisition/clearance of others. Methods: Data came from the following studies: Ludwig-McGill (n=2462), HITCH (n=1038), McGill-Concordia (n=636), BCCR (n=1687), and CCCaST (n=10154). HPV DNA was assessed using PGMY/MY PCR protocols to permit genotyping of 37 genital types. For each pair combination we calculated the expected frequency of coinfection by assuming infections occur independently, and compared this with the observed frequency. We also constructed hierarchical regression models for each HPV vaccine type by including all other types as exposures. Kaplan-Meier curves and Cox proportional hazard models were used to evaluate sequential acquisition/clearance of HPV types according to presence/absence of vaccine-preventable types. Results: Multiple-type HPV infection was common across studies (range=0.26-0.65). The O/E ratio for most pair combinations was >1 and not significant, suggesting no interaction between HPV infections. For HPV 16, only type 52 was flagged as a candidate for replacement (O/E ratio<1; range=0.36-0.48). Results from other statistical approaches provided similar inference. Conclusions: HPV types generally do not compete during natural infection. Our analysis provides reassurance that TR is not expected post-vaccination.

Learning Areas:

Learning Objectives:
1. Describe what is meant by type replacement in the context of HPV vaccination. 2. Explain why the observed/expected ratio (for HPV co-infection involving vaccine target types with other HPV types) is a useful measure for evaluating the potential for type replacement.

Keywords: Cancer Prevention, Epidemiology

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am a PhD candidate working in the field of cervical cancer research.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

See more of: Epidemiologic Methods
See more of: APHA-Student Assembly